<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882878</url>
  </required_header>
  <id_info>
    <org_study_id>CR109011</org_study_id>
    <secondary_id>2020-005569-14</secondary_id>
    <secondary_id>80202135SLE2001</secondary_id>
    <nct_id>NCT04882878</nct_id>
  </id_info>
  <brief_title>A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in&#xD;
      participants with active systemic lupus erythematosus (SLE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SLE is a complex, immune-mediated inflammatory disorder of unknown etiology that can affect&#xD;
      almost any organ system and follows a waxing and waning disease course. In SLE, the immune&#xD;
      system attacks the body cells and tissues and the resulting inflammation and tissue damage&#xD;
      can harm the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system.&#xD;
      Nipocalimab is a fully human aglycosylated immunoglobulin (Ig)G1 monoclonal antibody designed&#xD;
      to selectively bind, saturate, and block the IgG binding site on the endogenous neonatal&#xD;
      fragment crystallizable receptor (FcRn). Thus, nipocalimab, a FcRn antibody, has potential in&#xD;
      treatment of SLE through lowering of pathogenic IgGs and immune complexes. The study will&#xD;
      consist of a Screening Period (less than or equal to [&lt;=] 6 Weeks), double-blind Treatment&#xD;
      Period (52 Weeks), and a Follow-up Period (6 Weeks). Key safety assessments will include&#xD;
      adverse events (AEs), serious adverse events (SAEs), adverse events of special interests&#xD;
      (AESIs), clinical laboratory tests (hematology, chemistry, urinalysis, and lipid profile) and&#xD;
      vital signs. The total duration of the study is up to 64 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2021</start_date>
  <completion_date type="Anticipated">May 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 6, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4 Composite Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>SLE SRI-4 composite response is a composite of at least 4-point improvement in SLE Disease Activity Index 2000(SLEDAI-2K), no worsening in British Isles Lupus Assessment Group (BILAG), no worsening in Physician's Global Assessment of Disease Activity score (PGA) and not meeting study treatment failure criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Baseline Active Mucocutaneous Lupus Manifestations (Cutaneous Lupus Erythematosus Disease Area and Severity Index [CLASI] Activity Score &gt;= 6) Achieving &gt;= 50 Percent (%) Reduction in the CLASI Activity Score at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants achieving at least 50% improvement in CLASI Activity Score at Week 24 will be reported in participants with a CLASI Activity Score of 6 or greater at baseline. Cutaneous lupus disease activity and severity will be measured by the CLASI. The CLASI is an instrument to assess the disease activity and damage caused to the skin for cutaneous lupus erythematosus participants with or without systemic involvement. The CLASI consists of 2 scores; the first summarizes the activity of the disease while the second is a measure of the damage caused by the disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Baseline Arthritis (with at Least 4 Active Joints at Baseline) Achieving &gt;= 50% Reduction in Active Joints at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants with baseline arthritis (with at least 4 active joints at baseline) achieving &gt;= 50% reduction in active joints at Week 24 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with &gt;= 4 Point Improvement in SLE Disease Activity Index 2000 (SLEDAI-2K) at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants achieving at least 4 point improvement in SLEDAI-2K will be reported. The SLEDAI-2K is an established, validated SLE activity index. It is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE participants at the time of the visit or in the previous 30 days; the index is weighted according to the feature. Features are scored by the assessing physician if present at the time of the visit or within the last 30 days, with more severe features having higher scores, and then simply added to determine the total SLEDAI-2K score, which ranges from 0 to 105, with higher scores representing increased disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving the British Isles Lupus Assessment Group (BILAG) Composite Lupus Assessment (BICLA) Response at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>Percentage of participants achieving BICLA Response (BILAG-2004 disease activity improvement without worsening, and without worsening of SLEDAI-2K or PGA compared to baseline) at Week 24 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Flare Through Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Time to first flare through Week 24, with flare defined as either 1 or more new BILAG A or 2 or more new BILAG B scores will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving SRI-4 Composite Response at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants achieving SRI-4 composite response at Week 52 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Receiving &gt;= 10 milligram/day (mg/day) Prednisone or Equivalent at Baseline who Achieve Week 6-16 Glucocorticoid (GC) Taper Goal (at Week 16 to &lt;= 7.5 mg/day Prednisone or Equivalent) and Maintain that Reduction Until Week 24</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Percentage of participants receiving &gt;= 10 mg/day prednisone or equivalent at baseline who achieve Week 6-16 GC taper goal (at Week 16 to &lt;= 7.5 mg/day prednisone or equivalent) and maintain that reduction until Week 24 will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) Through Week 58</measure>
    <time_frame>Up to Week 58</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent Serious Adverse Events (SAEs) Through Week 58</measure>
    <time_frame>Up to Week 58</time_frame>
    <description>SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product. Treatment-emergent SAEs are defined as SAEs with onset or worsening on or after date of first dose of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent Adverse Events of Special interests (AESIs) Through Week 58</measure>
    <time_frame>Up to Week 58</time_frame>
    <description>Percentage of participants with treatment-emergent AESIs will be reported. Treatment-emergent adverse events associated with the following situations are considered as AESIs: infections that are severe or require intravenous anti-infective or operative/invasive intervention, hypoalbuminemia with albumin less than (&lt;) 20 gram/liter (g/L) (&lt;2.0 gram/deciliter [g/dL]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Treatment-emergent AEs leading to treatment discontinuation Through Week 58</measure>
    <time_frame>Up to Week 58</time_frame>
    <description>Percentage of participants with treatment-emergent AEs leading to discontinuation of study intervention will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Change from Baseline in Laboratory Parameters Over Time</measure>
    <time_frame>Up to Week 58</time_frame>
    <description>Number of participants with change from baseline in laboratory parameters (hematology, chemistry, urinalysis and lipid profile) over time will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Change from Baseline in Vital Signs Parameters Over Time</measure>
    <time_frame>Up to Week 58</time_frame>
    <description>Number of participants with change from baseline in vital sign parameters (temperature, pulse/heart rate, respiratory rate, and blood pressure) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Nipocalimab Over Time</measure>
    <time_frame>Up to Week 58</time_frame>
    <description>Serum concentrations of nipocalimab over time in participants receiving active study intervention will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Antibodies to Nipocalimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [Nabs])</measure>
    <time_frame>Up to Week 58</time_frame>
    <description>Number of participants with antibodies to nipocalimab (ADAs and Nabs) in participants receiving active study intervention will be reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo intravenously (IV) every two weeks (q2w) through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and Glucocorticoids [GCs]).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Nipocalimab Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive nipocalimab dose 1 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Nipocalimab Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive nipocalimab dose 2 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered intravenously.</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nipocalimab</intervention_name>
    <description>Nipocalimab dose 1 and dose 2 will be administered intravenously.</description>
    <arm_group_label>Group 2: Nipocalimab Dose 1</arm_group_label>
    <arm_group_label>Group 3: Nipocalimab Dose 2</arm_group_label>
    <other_name>JNJ-80202135</other_name>
    <other_name>M281</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard-of-care treatment</intervention_name>
    <description>Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_label>Group 2: Nipocalimab Dose 1</arm_group_label>
    <arm_group_label>Group 3: Nipocalimab Dose 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has a clinical diagnosis of systemic lupus erythematosus (SLE) greater than or equal&#xD;
             to (&gt;=) 6 months prior to the screening visit and according to Systemic Lupus&#xD;
             International Collaborating Clinics (SLICC)-2012 classification criteria: at least 4&#xD;
             criteria fulfilled, with at least 1 clinical criterion and 1 immunologic criterion&#xD;
&#xD;
          -  Has at least 1 BILAG (british isles lupus assessment group) A and/or 2 BILAG B scores&#xD;
             observed during screening&#xD;
&#xD;
          -  Must have at least moderately active SLE, as defined as systemic lupus erythematosus&#xD;
             disease activity index 2000 (SLEDAI-2K) score &gt;= 6 at screening visit. Must also have&#xD;
             SLEDAI 2K &gt;= 4 for clinical features (that is, SLEDAI-2K score excluding headache and&#xD;
             laboratory abnormalities) present at Week 0 prior to randomization&#xD;
&#xD;
          -  Has a CLASI (cutaneous lupus erythematosus disease area and severity index) activity&#xD;
             score of at least 6 (excluding diffuse non-inflammatory alopecia) or at least 4 joints&#xD;
             with pain and signs of inflammation (active joints) at screening or at Week 0, or both&#xD;
&#xD;
          -  At least 1 unequivocally positive autoantibody test including antinuclear antibodies&#xD;
             (ANA) (&gt;= 1:80) and/or anti-double stranded deoxyribonucleic acid (dsDNA) antibodies&#xD;
             (level &gt;= 75 international units/milliliter [IU/mL]) and/or anti-Smith antibodies&#xD;
             (&gt;120 Absorbance unit/milliliter [AU/mL]) detected during screening&#xD;
&#xD;
          -  Must be receiving 1 or more of the following protocol-permitted, systemic&#xD;
             standard-of-care treatments prior to first administration of study intervention at a&#xD;
             stable dose: oral glucocorticoids, antimalarial or up to 2 immunomodulatory drugs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of, severe, progressive, or uncontrolled renal disease, with the&#xD;
             exception of active lupus nephritis (LN). Have severe active LN as determined by&#xD;
             sponsor (or designee) adjudication&#xD;
&#xD;
          -  Has any unstable or progressive manifestation of SLE that is likely to warrant&#xD;
             escalation in therapy beyond permitted background medications&#xD;
&#xD;
          -  Has other inflammatory diseases that might confound the evaluations of efficacy&#xD;
&#xD;
          -  Has a severe infection including opportunistic infections requiring parenteral&#xD;
             anti-infectives, and/or hospitalization within 8 weeks prior to screening&#xD;
&#xD;
          -  Has received a single B-cell targeting agent within 3 months prior to first&#xD;
             administration of study intervention&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Valerius Medical Group &amp; Research Center</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Millennium Clinical Trials, LLC</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bay Area Arthritis and Osteoporosis</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Millennium Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dr. Ramesh Gupta</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Amarillo Center for Clinical Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Precision Comprehensive Clinical Research Solutions</name>
      <address>
        <city>Colleyville</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Epic Medical Research</name>
      <address>
        <city>Red Oak</city>
        <state>Texas</state>
        <zip>75154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatology &amp; Pulmonary Clinic</name>
      <address>
        <city>Beckley</city>
        <state>West Virginia</state>
        <zip>25801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Médico Reumatológico (OMI)</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Privado de Medicina Familiar</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1417EYG</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Médico Dra. Rivera (Fundación Respirar)</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1426ABP</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clínica Adventista Belgrano</name>
      <address>
        <city>Ciudad De Buenos Aires</city>
        <zip>C1430EGF</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Reumatologia - Ir Medical Center S.A.</name>
      <address>
        <city>Mendoza</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas Tucumán</name>
      <address>
        <city>San Miguel De Tucuman</city>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT 'St. Ivan Rilski'</name>
      <address>
        <city>Sfia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Reumatologia y Ortopedia</name>
      <address>
        <city>Barranquilla</city>
        <zip>0000</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa</name>
      <address>
        <city>Barranquilla</city>
        <zip>080001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación en Reumatología y especialidades médicas S.A.S. - CIREEM S.A.S.</name>
      <address>
        <city>Bogotá</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IPS Medicity SAS</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Servimed S.A.S</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Preventive Care Ltda</name>
      <address>
        <city>Chia</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Betegapolo Irgalmas Rend - Budai Irgalmasrendi Korhaz</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz</name>
      <address>
        <city>Gyula</city>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Chibahigashi National Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8712</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-8563</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Center for Global Health and Medicine, Kohnodai hospital</name>
      <address>
        <city>Ichikawa</city>
        <zip>272-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St.Marianna University School of Medicine</name>
      <address>
        <city>Kanagawa</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Osaka Minami Medical Center</name>
      <address>
        <city>Kawachi-Nagano</city>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya-City</city>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Nagoya Medical Center</name>
      <address>
        <city>Nagoya-shi</city>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka Medical and Pharmaceutical University Hospital</name>
      <address>
        <city>Takatsuki</city>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Luke's International Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fujita Health University Hospital</name>
      <address>
        <city>Toyoake</city>
        <zip>470-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Tsukuba</city>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki Nr 2 w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nzoz Bif-Med</name>
      <address>
        <city>Bytom</city>
        <zip>41-902</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Diamond Clinic</name>
      <address>
        <city>Krakow</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>NZOZ Lecznica MAK-MED. S.C.</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne</name>
      <address>
        <city>Poznan</city>
        <zip>61-113</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prywatna Praktyka Lekarska, Prof. UM dr hab. med. Paweł Hrycaj</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kliniczny Szpital Wojewodzki nr 1 w Rzeszowie</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medycyna Kliniczna</name>
      <address>
        <city>Warszawa</city>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. Eleonory Reicher</name>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>GBUZ Regional Clinical Hospital for War Veterans</name>
      <address>
        <city>Kemerovo</city>
        <zip>650000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLL Medical Center Revma-Med</name>
      <address>
        <city>Kemerovo</city>
        <zip>650070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rostov Regional Clinical Dermatovenerological Dispensary</name>
      <address>
        <city>Rostov</city>
        <zip>344007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Leningrad region clinical hospital</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panorama Medical Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Excellentis Clinical trial Consultants</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winelands Rheumatology Centre</name>
      <address>
        <city>Stellenbosch</city>
        <zip>7600</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Vall D Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Ramon Y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitari Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>88301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Medical University</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise 'Chernihiv Regional Hospital' of Chernihiv Regional Council</name>
      <address>
        <city>Chernihiv</city>
        <zip>14029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise of Kharkiv Regional Council 'Regional Clinical Hospital'</name>
      <address>
        <city>Kharkiv</city>
        <zip>61204</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center 'Ok Clinic' of International Institute of Clinical Research LLC</name>
      <address>
        <city>Kyiv</city>
        <zip>02091</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medbud-Clinic LLC</name>
      <address>
        <city>Kyiv</city>
        <zip>03037</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'</name>
      <address>
        <city>Kyiv</city>
        <zip>03049</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center 'Consylium Medical'</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council</name>
      <address>
        <city>Odessa</city>
        <zip>65025</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ME 'Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil'</name>
      <address>
        <city>Poltava</city>
        <zip>36011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MNPE 'Vinnytsia Regional Clinical Hospital named after M.I. Pyrogov of Vinnytsia Regional Council'</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center LLC 'Modern Clinic'</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69600</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR109011</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>October 26, 2021</last_update_submitted>
  <last_update_submitted_qc>October 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinical trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

